Thursday 30 October 2003
- congenital hemangiomas (RICH and NICH )
- juvenile hemangioma (infantile hemangioma )
- targetoid hemosiderotic hemangioma
- epithelioid hemangioma
- lymphatic malformations
- lymphatic tumors
malignant vascular tumors
- Kaposi sarcoma
glomus tumors (glomic tumors )
According to the localization
Vascular tumors with lobular architecture
β-Adrenergic receptor expression in vascular tumors (22743651)
Propranolol has recently emerged as an effective therapy for infantile hemangiomas causing regression.
The β-adrenergic receptor (AR) antagonist is thought to cause vasoconstriction by its effect on nitric oxide, block angiogenesis by its effect on vascular endothelial growth factor (VEGF), and induce apoptosis.
The expression of β2-AR (B2-AR) and its phosphorylated form (B2-ARP) have been identified in a case of infantile hemangioma that responded to propranolol treatment.
Although immunohistochemical expression of the receptors does not necessarily indicate that similar pathways of responsiveness to β-blockade are present, it does raises the possibility that β-blockade could potentially affect apoptosis and decrease responsiveness to VEGF.
β-Adrenergic receptor expression in vascular tumors. Chisholm KM, Chang KW, Truong MT, Kwok S, West RB, Heerema-McKenney AE. Mod Pathol. 2012 Jun 29. PMID: 22743651